IGA NEPHROPATHY
Clinical trials for IGA NEPHROPATHY explained in plain language.
Never miss a new study
Get alerted when new IGA NEPHROPATHY trials appear
Sign up with your email to follow new studies for IGA NEPHROPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug shows promise in slowing rare kidney disease
Disease control OngoingThis study tests an experimental drug called atacicept in 376 adults with IgA nephropathy, a kidney disease that can lead to kidney failure. The goal is to see if atacicept can reduce protein in the urine and slow the loss of kidney function. Participants receive either the drug …
Matched conditions: IGA NEPHROPATHY
Phase: PHASE3 • Sponsor: Vera Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 04:37 UTC
-
New hope for kidney disease: experimental drug aims to slow damage in IgA nephropathy
Disease control OngoingThis study tests an experimental drug called BION-1301 in 383 adults with IgA nephropathy, a kidney disease that can lead to kidney failure. The goal is to see if the drug can slow the loss of kidney function and reduce protein in the urine over two years. Participants receive ei…
Matched conditions: IGA NEPHROPATHY
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
New drug BION-1301 tested for kidney disease
Disease control OngoingThis study tests a new drug called BION-1301 in healthy people and adults with IgA nephropathy, a kidney disease. The goal is to check if the drug is safe and how the body processes it. About 103 participants will be involved in this early-stage trial.
Matched conditions: IGA NEPHROPATHY
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
New drug ARO-CFB aims to control kidney disease in early trial
Disease control OngoingThis early-stage study tests a new drug, ARO-CFB, in healthy volunteers and people with a kidney disease called IgA nephropathy. The main goal is to check safety and how the drug moves through the body. Participants receive one or two doses of the drug or a placebo.
Matched conditions: IGA NEPHROPATHY
Phase: PHASE1 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated May 19, 2026 12:00 UTC